Gapping up
In reaction to strong earnings/guidance:
- ORCL +11.3%, CMC +8.6%, HAIN +5.5%, CO +4.5%, APOG +4.1%
M&A news:
- SPLS +6.8% (Sycamore Partners nearing M&A deal to purchase SPLS, according to Reuters)
Other news:
- TROV +13.7% (enters into agreement with a worldwide, premier biopharmaceutical company to provide Trovera urine circulating tumor DNA biomarker tests and services)
- OVAS +8.2% (appoints Christopher Kroeger as CEO effective September 1; will restructure its organization)
- NRZ +3.1% ( increases quarterly dividend to $0.50 per common share from $0.48 per common share)
- NVS +2.7% (reports Phase 3 data for ACZ885 demonstrating reduction in cardiovascular risk)
- SHPG +2.3% (receives EMA Validation of Veyvondi)
- FGEN +1% (confirms receipt of Orphan Drug Designation by the FDA for Pamrevlumab)
Analyst comments:
- ATVI +1.3% (target raised to $70 from $60 at Oppenheimer)
- VLO +1.2% (upgraded to Buy from Hold at Jefferies)